Treats hypertension. ANDA 76674, held by Macleods Pharmaceuticals. Hydrochlorothiazide; Lisinopril.
As of Nov 21, 2026, ANDA 76674 (Lisinopril and Hydrochlorothiazide), held by Macleods Pharmaceuticals, was first approved by FDA on Oct 5, 2004, with 10 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Lisinopril and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 5, 2004 | Original application | Approved | None posted |
| Lisinopril and Hydrochlorothiazide12.5MG;10MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide12.5MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Lisinopril and Hydrochlorothiazide25MG;20MG · tablet;oral | Hydrochlorothiazide; Lisinopril | Rx |
| Aug 20, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| Jul 16, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Nov 18, 2015 | Supplement 17Labeling · Standard review | Approved | None posted |
| Nov 18, 2015 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 18, 2015 | Supplement 14Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 13Labeling · Standard review | Approved | None posted |
| Feb 26, 2014 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 19, 2010 | Supplement 11Labeling | Approved | None posted |
| Jun 8, 2006 | Supplement 5Labeling | Approved | None posted |
| Jan 31, 2006 | Supplement 2Labeling | Approved | None posted |
| Oct 5, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters